Fields

Tumor Metabolomics Analysis and Drug Screening

Keypoints

1) Analyzing metabolic activation/inhibition of organoid;

2) Establishing disease modeling to propose therapeutic solutions/drug screening.

Contents

At the organoid level, establish a strategy to analyze the activation of specific metabolic pathways after the tumorigenesis model of organoids, explore the key factors of specific metabolic activation, and then block the metabolic pathways specifically activated by tumor organoids for treatment.

Advancements

1) The important role of metabolic activation/inhibition in tumorigenesis can be precisely analyzed;

2）Analysis of key targets regulating metabolic activation/inhibition during tumorigenesis and elaboration of their regulatory mechanisms;

3）Based on the blocking of tumor-specific metabolic modes, screening drugs with specific blocking effect on tumor metabolism.

Disturbed one-carbon metabolism in hepatoblastoma: S-adenosylmethionine (SAM) is downregulated and S-adenosyl-L-homocysteine (SAH) is upregulated in YAP1-activated hepatoblastoma-like organs.

Methyltransferase inhibitor screen: the small molecule chemotaxis BIX 01294 can inhibit hepatoblastoma by blocking G9a activation and thereby achieving inhibition.

Protein & Cell, 2021, IF=14.9

Metabolomics, organoid gene function studies, tumor metabolomics, tumorigenesis models

Related Keywords：

Tumor metabolism, tumor microenvironment, glycolysis, one-carbon cycle, small molecule inhibitors

For more details, please contact:

400-600-8315